On April 18, 2023 BullFrog AI Holdings, Inc. (Nasdaq: BFRG) ("Bullfrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, reported an exclusive license agreement with Johns Hopkins University for prodrug compositions of mebendazole (Press release, Bullfrog AI, APR 18, 2023, View Source [SID1234635572]). The exclusive license was signed on October 13, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The world-wide, royalty-bearing license includes the rights to commercialize N-substituted prodrugs of mebendazole that demonstrate improved solubility and bioavailability relative to the parent compound. The license covers prodrug compositions and use for treating disease as claimed in multiple US and worldwide patent applications.

"This asset is another key addition to our oncology development pipeline and provides us with an opportunity to demonstrate how our AI/ML technology can turn promising drug candidates into tangible therapies in a cost-effective and efficient manner," said BullFrog AI’s founder and CEO, Vin Singh, "We are extremely proud of our expanding relationship with Johns Hopkins. We look forward to working with strategic partners to advance the development and monetize this promising asset for the treatment of glioblastoma and possibly additional oncology indications."